News & Media

Learn more about the latest happenings at Otsuka. Select to see US news or read our press releases. You can also stay up to date with our global news in the link below.

Media Contact:

Robert Murphy

Senior Director, External Communications,
Otsuka America Pharmaceutical, Inc

Phone:

609-249-7262

Email:

robert.murphy@otsuka-us.com

Featured News

Press Release

JAMA Psychiatry Publishes Results of Otsuka and Lundbeck's Phase 3 Trial of Brexpiprazole in Combination with Sertraline in Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults

Otsuka Pharmaceutical Development & Commercialization, Inc. and Lundbeck LLC today announced that the full results of a Phase 3 trial of brexpiprazole in combination with sertraline for the treatment of PTSD in adults have been published in JAMA Psychiatry.

December 18, 2024

Press Release

Otsuka Provides Update on Sibeprenlimab, an Investigational Monoclonal Antibody for the Treatment of IgA Nephropathy in Adults

Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka Pharmaceutical, Co. Ltd. (Otsuka) announce the decision to submit a Biologics License Application (BLA) in the U.S. for sibeprenlimab, an investigational drug for the treatment of immunoglobulin A nephropathy (IgA nephropathy) in adults, in the first half of 2025. The update follows a recent meeting with the U.S. Food & Drug Administration to discuss the positive interim analysis results from the Phase 3 VISIONARY study (NCT05248646).

November 19, 2024

All news

Press Release

New Report Reveals U.S. Family Caregivers Perform Equivalent of a Staggering $873.5 Billion Worth of Labor, Would Surpass Revenue of Top Global Companies

Findings released today from a new valuation study conducted by Columbia University Mailman School of Public Health, and sponsored by Otsuka America Pharmaceutical, Inc. reveal that if family caregiving was a business entity it would be the largest revenue-generating company in the world

October 24, 2024

Press Release

Otsuka Announces Positive Interim Results from the Phase 3 Trial of Sibeprenlimab for the Treatment of Immunoglobulin A Nephropathy in Adults

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd. today announce positive topline interim data from the ongoing Phase 3 clinical trial of sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgA nephropathy) in adults.

October 22, 2024

Press Release

New Study Finds Family Caregivers Would Earn Six Figures If Paid A Salary

Findings released from a new compensation study, conducted by Salary.com and sponsored by Otsuka America Pharmaceutical, Inc. (Otsuka), reveal caregivers of loved ones with Alzheimer's or other dementias would earn a six-figure salary—approximately $114,000 on average—if paid for the daily care they provide.

October 14, 2024

Discover more mental
health and caregiver
perspectives.

VALUED MINDS NEWS

News & Media

Media Contact:

Featured News

All news

Discover more mental health and caregiver perspectives.

Discover more mental
health and caregiver
perspectives.